theranos	LDT Validation Report	Theranos Lithium Assay	Rev:
		CL RPT-14064	1
Description	Validation Report for Modified Siemens Assay of Lithium in EDTA Plasma		
Originator: Curtis Schneider		Date: 10/15/2013	

Validation of Modified Siemens Lithium Assay

Author(s):

Signature:	Date: 12/12/13
Name: Paul Patel, Ph.D.	Title: Team Lead, General Chemistry

Reviewer(s):

Signature:	Date:
Name:	Title:

Signature:	Date: 12/13/2013
Name: Daniel Young, Ph.D.	Title: Vice President

Approver(s):

Signature:	Date: 12/12/2013
Name: Adam Rosendorff, M.D.	Title: Laboratory Director

9/19/15

Sunil S. Dhawan M.D.

Theranos Internal Only

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

Lithium Plasma Assay

Theranos Internal Only

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

Overview

Lithium alters the intraneuronal metabolism of catecholamines by an unknown mechanism. It is used to suppress the manic phase of manic-depressive psychosis.

Lithium is distributed throughout the total water spaces of the body and is excreted primarily by the kidney.

Toxicity from lithium salts leads to ataxia, slurred speech, and confusion. Since the concentration of lithium in the serum varies with the time after the dose, blood for lithium determination should be drawn at a standard time, preferably 8 to 12 hours after the last dose (trough values).

I. Method Principle

The concentration of lithium in the sample is proportional to the increase in absorbance, which is due to the formation of a lithium complex with an aza-crown-ether. The reaction absorbance is measured at 505/694 nm.

Reaction Equation



Theranos Internal Only

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

II. Definitions and Abbreviations

The following definitions and abbreviations are used in this document and related documents and attachments:

a. **Accuracy:** Accuracy is defined by CLSI as the closeness of agreement between a test result and an accepted reference value. Method accuracy is used in a different sense by the American Association of Pharmaceutical Scientists where it is expressed as percent relative error (%RE). Trueness, a related CLSI term, is the closeness of agreement between the average of a number of replicate measured quantity values and a reference quantity value.

b. **Analyte:** Component represented in the name of a measurable quantity. The closely related term measureand is defined as the particular quantity subject to measurement.

c. **Analytical sensitivity:** There are several alternative uses of this term. Most commonly, and for the purposes of this Validation Plan, it is used interchangeably with limit of detection. It is also used to describe the ability of an analytical method to assess small variations of the concentration of an analyte, such as the slope of the calibration curve (IUPAC).

d. **Analytical specificity:** Ability of a test or procedure to correctly identify or quantify an entity, including in the presence of interfering substance(s) or phenomena.

e. **Calibration:** Set of operations that establish, under specified conditions, the relationship between values of quantities indicated by a measuring instrument or measuring system, or values represented by a material measure or a reference material, and the corresponding values realized by standards. Under CLIA, calibration refers to the process of testing and adjusting an instrument, kit, or test system, to provide a known relationship between the measurement response and the value of the substance being measured by the test procedure (42 CFR 493.1217).

f. **Calibrator:** A substance, material, or article intended to be used to establish the measurement relationships of a diagnostic medical device.

g. **CLIA:** Clinical Laboratory Improvement Amendments of 1988. Congressional legislation that defined and requires specific quality assurance practices in clinical laboratories.

h. **CLSI:** Clinical and Laboratory Standards Institute.

Theranos Internal Only

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

i. **Coefficient of Variation:** The ratio of the standard deviation to the average, often multiplied by 100 and expressed as a percentage, abbreviated as %CV .

j. **Colorimetry:** A technique used to determine the concentration of colored compound(s) in solution.

k. **Interfering substance:** A substance or quantity thereof that is not the measurand but that affects the result of the measurement.

l. **IUPAC:** International Union of Pure and Applied Chemistry

m. **LDT:** Laboratory –developed Test.

n. **Linearity:** Linearity is the ability of a quantitative analytical method to provide results that are directly proportional to the concentrations of an analyte in test samples, within a given measuring interval. It is an important parameter to confirm when evaluating an analytical method because it verifies correct interpolation of results between points.

o. **LMR:** Lower end of the measuring range is the lowest level at which defined conditions, including all stated characteristic of the method, are met.

p. **LoB:** Limit of Blank is the highest value in a series of results on a sample that contains no analyte.

q. **LoD:** Limit of Detection is the lowest amount of analyte in a sample that can be detected with stated probability, although perhaps not quantified as an exact value.

r. **LoQ:** When used without a prefix, the Limit of Quantitation is the lowest actual concentration at which an analyte is reliably detected and at which uncertainty of the test result is less than or equal to the goal set by the manufacturer or laboratory. The term may also be used with prefixes L for lower (LLOQ) and U for upper (ULOQ), respectively. Note: LoB < LoD ≤ LoQ.

s. **Matrix:** All components of a material system, except the analyte. A specimen matrix is the biological milieu in which an analyte exists (e.g., plasma, serum, urine, or other body fluids).

Theranos Internal Only

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

t. **Measuring Interval (reportable range; analytical measurement range or AMR):** A measuring interval consists of all numeric values between the lower and upper numeric values for which a method can produce quantitative results suitable for clinical use. Where applicable, a linearity study is frequently used to establish or verify the measuring interval that can be reported for a measurement method. Alternatively, the lower limit of the measuring interval may be assigned as the LoQ (LLOQ).

u. **Precision:** Precision is the closeness of agreement between indications or measured quantity values obtained by replicate measurements on the same or similar objects under specified conditions. It is usually expressed numerically in terms of standard deviation (SD) or percent Coefficient of Variation (%CV).

v. **Reference interval:** The interval between and including two reference limits. It is common practice to define a reference limit so a stated fraction of the reference values is less than or equal, or greater than or equal, to the respective upper or lower limit.

w. **SOP:** Standard Operating Procedure.

x. **Spectrophotometry:** The quantitative measurement of the transmission (or reflection) properties of a material as a function of wavelength.

y. **Testing System:** The entirety of the testing process, including instrument, sample, reagents, supplies, and procedures. Personnel are sometimes included in the definition.

Theranos Internal Only

III. Pre-clinical Validation

a. Analytical Measurement Range

i. Limits of Blank, Detection and Quantitation

The limits of blank, detection, and quantitation were determined to be 0.02 mmol/L, 0.11 mmol/L and 0.37 mmol/L respectively.

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

Limit of blank

CLSI guideline EP17-A section 4.3.1

Level	Number of samples	N	Mean	SD
Blank	1	20	0.005	0.010
Alpha	5%			
Parametric LoB	0.021			

Limit of detection

CLSI guideline EP17-A section 4.3.2

Level	Number of samples	N	Pooled SD
Low	1	20	0.055
Beta	5%		
Parametric LoD	0.112		

Limit of quantitation

CLSI guideline EP17-A section 5.1

Level	Number of samples	N
Low	1	20
Bias	-0.030	
Pooled imprecision	0.055	
95% total error	-0.137	
Allowable error	0.08	

The lower limit of quantitation has been established at 0.37 mmol/L (14.8% CV and 92.6% recovery).

ii. Linearity

The Analytical Measurement Range (AMR) including linear measurement interval has been determined by Siemens. Refer to the Analytical Range section of the manufacturer product information insert for additional details.

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

b. Analytical Specificity

The analytical specificity for this assay was determined by testing the effect of hemoglobin (100 mg/dL), bilirubin (10 mg/dL) and triglycerides (400 mg/dL) on plasma samples spiked with the interferents and then compared with un-spiked controls. Lithium concentration at which the interference testing was performed at was 0.93 mmol/L Non-interference was defined as the mean result from testing of spiked samples within 10% of the mean of the un-spiked samples. Recoveries were within 90.8% to 105.5% (see table below).

Table 1. Interference Testing For Lithium.

Analyte (mg/dL)	% Recovery		
	Interferent		
	Bilirubin (10 mg/dL)	Hemoglobin (100 mg/dL)	Triglycerides (400 mg/dL)
Lithium	90.8	105.5	95.4

No significant interference was observed

c. Precision

Theranos Internal Only

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

Level = Level 1

Number of observations	80
Number of runs	40
Number of days	20
Runs per day	2
Replicates per run	2
Mean	0.594

	SD	95% CI	CV	Allowable Total SD
Repeatability	0.041	0.034 to 0.052	6.9%	-
Between-run	0.032		5.4%	-
Between-day	0.017		2.8%	-
Within-laboratory	0.055	0.047 to 0.066	9.2%	0.119

Imprecision is less than allowable total imprecision: 20% upto 3mM then 20%.

Level = Level 2

Number of observations	80
Number of runs	40
Number of days	20
Runs per day	2
Replicates per run	2
Mean	1.098

	SD	95% CI	CV	Allowable Total SD
Repeatability	0.056	0.046 to 0.071	5.1%	-
Between-run	0.000		0.0%	-
Between-day	0.112		10.2%	-
Within-laboratory	0.125	0.098 to 0.173	11.4%	0.220

Imprecision is less than allowable total imprecision: 20% upto 3mM then 20%.

The percent CV reported as zeros in the above precision summary are most likely a consequence of rounding the values in StatisPro.

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

IV. Clinical Validation

a. Method Comparison with Predicate (Accuracy/Comparability)

To test the accuracy of the assay on the Theranos System, twenty (20) unique patient samples were screened on the predicate method (Siemens, Advia) and on the Theranos method. Using the predicate method nine (9) values were below the therapeutic range, three (3) were within the therapeutic range (1.0 – 1.2 mM) and eight (8) were above the toxic level (>1.5 mM). Based on the results of the data examination, either a simple linear regression or alternative procedures were used to estimate expected (average) bias and the confidence interval of expected bias at the desired medical decision level(s) as per CLSI guidance EP09-A2. StatisPro was used for bias calculations. These estimates were compared with internal criteria to judge the acceptability of the Theranos method. Each sample was run in duplicate on the predicate, and the average used for comparison to the Theranos method. Some samples were stored before analysis on both methods. If the confidence interval for the predicted bias includes the defined acceptable bias or if the acceptable bias is greater than the higher limit of the confidence interval of the predicted bias, then the data do not show that the bias of the Theranos method is different from the acceptable bias or there is a high probability (97%) that the predicated bias is acceptable, respectively. The acceptable bias at each medical decision level was determined based on the total allowable error (TEa) minus the measured precision at the level closest to that decision level. Total allowable error (TEa) was taken from American Proficiency Institute (API) peer proficiency testing criteria or CLIA proficiency testing criteria for acceptable analytical performance, as printed in the Federal Register February 28, 1992;57(40):7002-186, when available. The TEa for Lithium is 20%. The table below shows the allowable bias and precision at 2 levels (values shown in parentheses) and the corresponding closest medical decision limits.

Theranos Internal Use Only

Table 2. Allowable Bias and Precision at the Medical Decision Levels

Medical Decision Levels (mmol/L)	0.4 (0.59)	1.5(1.1)
Precision (%)	2.8	10.2
Allowable Bias (%)	17.2	9.8

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.



Figure 1. Graph showing Theranos method versus Predicate Method (Siemens Advia).

Simple linear regression was used to establish a slope, intercept and an r^2. The slope, intercept and clinical correlation were determined to be 1.11, -0.03 and 0.86 respectively.

Comparability

CLSI guideline EP09-A2-IR section 7

Level ID	Value	Difference	SE	95% CI	Allowable difference
	1.200000	0.0950703	0.05265000	-0.0155432 to 0.2056839	0.1200000
	1.500000	0.1274401	0.06056400	0.0001998 to 0.2546803	0.2580000

Difference is less than allowable bias: 10% upto 1.5mmol/L then 17.2%.

The difference between the two methods is not greater than the allowable difference. The performance requirement is verified.

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

b. Transference and Verification of Reference Interval (Venous)

Reference interval for this analyte has been replaced by therapeutic and toxic levels therefore verifying venous sample reference ranges is not required for Lithium.

c. Verification of Reference Interval with Finger Stick Samples

Verifying finger stick sample reference ranges not required for Lithium.

The level determined for Lithium toxicity for a finger stick sample was determined to be > 1.6 mmol/L.

theranos Internal Only

VI. Stability

a. Reagents

On-board Reagent Stability

System	Stability Without Reagent Container Inserts	Stability With Reagent Container Inserts*
ADVIA 1200	30 days	45 days
ADVIA 1650/1800	30 days	60 days
ADVIA 2400	30 days	60 days

For all systems, unopened reagents are stable until the expiration date printed on the product label when stored at 2°C - 8°C. Do not freeze the reagents.

For additional details, refer to the Methods Introduction section of the system-specific Operator's Guide.

b. Sample

Plasma samples for lithium analysis are stable for 1 week at 2-8 °C, or at least 2 week at -20 °C.

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.

c. Calibrators

Siemens Chemistry Calibrators should be stored at 2-8 °C, protected from light, and are stable until the expiration date on the vial label. Opened calibrators are stable for 48 hours, except for total and direct bilirubin, which are stable for 8 hours.

REVISION HISTORY			
Revision Level	**Effective Date**	**Initiator**	**ECO Number**
A	11/10/2013	A. Rosendorff	CL ECO-00118
Section Number	**Description and Justification of Changes**		
All	Initial Release		

Theranos Internal Use Only

Any retransmissions, reproductions, dissemination or other use of these materials by persons or entities other than the intended recipient is prohibited. This document supersedes all earlier or previous documents unless approved in writing.